EA201591435A1 - Новая композиция соединения ацетаминофена без побочного эффекта на печень - Google Patents

Новая композиция соединения ацетаминофена без побочного эффекта на печень

Info

Publication number
EA201591435A1
EA201591435A1 EA201591435A EA201591435A EA201591435A1 EA 201591435 A1 EA201591435 A1 EA 201591435A1 EA 201591435 A EA201591435 A EA 201591435A EA 201591435 A EA201591435 A EA 201591435A EA 201591435 A1 EA201591435 A1 EA 201591435A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liver
acetaminophen
tween
polyoxyethylene
toxicity
Prior art date
Application number
EA201591435A
Other languages
English (en)
Other versions
EA029454B1 (ru
Inventor
Оливер Яопу Ху
Тунюань Ших
Original Assignee
Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн filed Critical Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн
Publication of EA201591435A1 publication Critical patent/EA201591435A1/ru
Publication of EA029454B1 publication Critical patent/EA029454B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Новая композиция соединения без побочных эффектов на печень и используемая для устранения токсичности, оказываемой на печень лекарственным средством ацетаминофеном (N-ацетил-пара-аминофенол). Композиция соединения содержит в своем составе: (а) фармацевтически эффективное количество ацетаминофена и (b) общеупотребительное безопасное и фармацевтически приемлемое вспомогательное вещество, которое можно комбинировать с одним или несколькими лекарственными средствами для снижения токсичности печеночного фермента CYP2E1 при метаболизме лекарства в печени. Соединение выбрано из следующей группы, включающей: Tween 20, микрокристаллическую целлюлозу, дикальцийфосфат, 23 лауриловый эфир полиоксиэтилена, сахарин, маннитол, простой алкиловый эфир полиоксиэтилена, сукралозу, пирролидон, натрия крахмала гликолят, акриловую синтетическую смолу S100, натриевую соль карбоксиметилцеллюлозы, полиоксипропилен полиоксиэтилена, ментол, гидроксипропилцеллюлозу с низкой степенью замещения, крахмал прежелатинизированный, гидратированные декстраты NF, лимонную кислоту, касторовое масло полиоксиэтилена, коллоидную двуокись кремния, сложный эфир алифатического ряда моностеарата полиэтиленгликоля, сорбиновую кислоту, лимонное масло, гидроксипропилцеллюлозу, сорбитол, ацесульфам калия, фталат гипромеллозы, моногидрат лактозы, мальтодекстрин, Бридж 58, Бридж 76, Tween 80, Tween 40, ПЭГ 400, ПЭГ 4000, ПЭГ 2000 и аналогичные соединения для снижения побочных эффектов, вызываемых токсичностью, оказываемой ацетаминофеном на печень.
EA201591435A 2013-11-13 2013-11-13 Новая композиция соединения ацетаминофена без побочного эффекта на печень EA029454B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/087049 WO2015070396A1 (zh) 2013-11-13 2013-11-13 无肝副作用的对乙酰胺基酚新复方组合

Publications (2)

Publication Number Publication Date
EA201591435A1 true EA201591435A1 (ru) 2016-05-31
EA029454B1 EA029454B1 (ru) 2018-03-30

Family

ID=53056618

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591435A EA029454B1 (ru) 2013-11-13 2013-11-13 Новая композиция соединения ацетаминофена без побочного эффекта на печень

Country Status (15)

Country Link
US (3) US10420737B2 (ru)
EP (2) EP3069733B1 (ru)
JP (1) JP2016520100A (ru)
KR (2) KR102017550B1 (ru)
CN (2) CN111904924A (ru)
DK (1) DK3069733T3 (ru)
EA (1) EA029454B1 (ru)
ES (1) ES2929945T3 (ru)
HR (1) HRP20221344T1 (ru)
HU (1) HUE060309T2 (ru)
LT (1) LT3069733T (ru)
PL (1) PL3069733T3 (ru)
PT (1) PT3069733T (ru)
RS (1) RS63704B1 (ru)
WO (1) WO2015070396A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3069733T3 (da) * 2013-11-13 2022-11-14 National Defense Education And Res Foundation Ny acetaminophenforbindelsessammensætning uden bivirkninger for leveren
BR112018005905B1 (pt) * 2015-09-24 2023-03-21 Sinew Pharma Inc Composto, composição farmacêutica, e, uso de um composto
JP2018534323A (ja) * 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
CA3090029A1 (en) * 2018-02-14 2019-08-22 Sinew Pharma Inc. Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap)
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
AU2018440280B2 (en) * 2018-09-03 2022-11-03 Jacob Biotech Ltd Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5584166A (en) * 1978-12-20 1980-06-25 Lion Hamigaki Kk Band for spongy medicine
ZA837556B (en) * 1982-11-15 1984-06-27 Upjohn Co Acetominophen and ibuprofen/flurbiprofen
JPS62502194A (ja) * 1985-03-18 1987-08-27 プロダクト・リソ−シズ・インタ−ナショナル・インコ−ポレイテッド エ−ロゾル発泡体
DE3678640D1 (de) * 1985-08-26 1991-05-16 Procter & Gamble Geschmack abdeckende zusammensetzungen.
JPH01190628A (ja) * 1988-01-21 1989-07-31 Sumitomo Pharmaceut Co Ltd 持続性坐剤
FR2646773B1 (fr) * 1989-05-12 1994-05-13 Chauvin Sa Laboratoire Composition pharmaceutique a base de paracetamol
DE69121098T2 (de) * 1990-04-04 1997-01-23 Berwind Pharma Service Wässrige filmbildende überzugszusammensetzungen aus maltodextrin und zellulosederivaten
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
WO1997044045A1 (en) * 1996-05-20 1997-11-27 Fuisz Technologies Ltd. Malatonin in combination with analgesics
US5858997A (en) * 1997-12-04 1999-01-12 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Method and composition for skin lightening
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
FR2798289B1 (fr) * 1999-09-15 2004-12-31 Cll Pharma Formes galeniques a delitement rapide en bouche et leur procede de preparation
TR200201112T2 (tr) * 1999-10-29 2002-12-23 Fmc Corporation Yenebilir kaplama kompozisyonu
ES2174734B1 (es) * 2000-11-03 2003-10-01 Belmac S A Lab Nueva formulacion galenica de paracetamol dispersable y soluble, procedimiento para su preparacion y aplicaciones.
KR100892333B1 (ko) * 2001-07-10 2009-04-08 테바 파마슈티컬 인더스트리즈 리미티드 0차, 0차-2상, 증가적 또는 감소적 약물 전달을 위한 약물전달 시스템
MXPA04001026A (es) * 2001-07-31 2005-06-20 Wyeth Corp Formulacion de sucralosa para disimular sabores desagradables.
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
EP1708684A2 (en) * 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
GB0330255D0 (en) * 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
WO2006129668A1 (ja) * 2005-05-30 2006-12-07 Meiji Seika Kaisha, Ltd. 糖衣を施した丸剤
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007050631A2 (en) * 2005-10-25 2007-05-03 Cima Labs Inc. Dosage form with coated active
US8048449B2 (en) * 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CA2690829A1 (en) * 2007-07-20 2009-01-29 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
BRPI0821871A2 (pt) * 2008-01-03 2015-06-16 Wockhardt Research Center Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno
KR20100134557A (ko) * 2008-01-11 2010-12-23 씨아이피엘에이 엘티디. 고체 약제학적 투여 제형
WO2010009572A1 (zh) * 2008-07-23 2010-01-28 国防教育研究基金会 含异烟碱酰胺（isoniazid, inh）低副作用的新复方
EP2405898A2 (en) * 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
JP2011046666A (ja) * 2009-08-28 2011-03-10 Lion Corp 医薬組成物
CN101695498A (zh) * 2009-10-26 2010-04-21 昆明理工大学 对乙酰氨基酚所致肝损伤保护药物及其应用
CA3065589C (en) * 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
WO2012075455A2 (en) * 2010-12-02 2012-06-07 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
CN108465110A (zh) * 2011-04-20 2018-08-31 教育研究基金会 无/低副作用的抗结核病药物复方
CN102988993B (zh) * 2011-09-13 2017-03-15 广东九明制药有限公司 复方对乙酰氨基酚片主要辅料的筛选和组成及其制备方法
JP5828280B2 (ja) * 2011-12-28 2015-12-02 ライオン株式会社 錠剤及びその製造方法
ES2414557B1 (es) 2012-01-16 2014-06-10 Novocat Farma, S.A. Composición acuosa de paracetamol para inyección
CN102600119B (zh) 2012-02-07 2013-03-27 海南卫康制药(潜山)有限公司 一种小儿对乙酰氨基酚组合物
CN103110629B (zh) * 2013-02-19 2014-03-19 青岛正大海尔制药有限公司 复方酚麻美敏滴丸及其制备方法
DK3069733T3 (da) * 2013-11-13 2022-11-14 National Defense Education And Res Foundation Ny acetaminophenforbindelsessammensætning uden bivirkninger for leveren
BR112018005905B1 (pt) * 2015-09-24 2023-03-21 Sinew Pharma Inc Composto, composição farmacêutica, e, uso de um composto
CA3090029A1 (en) * 2018-02-14 2019-08-22 Sinew Pharma Inc. Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap)

Also Published As

Publication number Publication date
US20170172950A1 (en) 2017-06-22
PL3069733T3 (pl) 2023-02-13
DK3069733T3 (da) 2022-11-14
EP3069733B1 (en) 2022-08-10
EA029454B1 (ru) 2018-03-30
US20190262289A1 (en) 2019-08-29
KR20170085607A (ko) 2017-07-24
CN111904924A (zh) 2020-11-10
EP4173619A2 (en) 2023-05-03
JP2016520100A (ja) 2016-07-11
CN105188756B (zh) 2020-06-12
KR101881074B1 (ko) 2018-08-17
KR102017550B1 (ko) 2019-09-03
HUE060309T2 (hu) 2023-02-28
HRP20221344T1 (hr) 2022-12-23
CN105188756A (zh) 2015-12-23
EP3069733A1 (en) 2016-09-21
WO2015070396A1 (zh) 2015-05-21
RS63704B1 (sr) 2022-11-30
PT3069733T (pt) 2022-11-09
US20230082397A1 (en) 2023-03-16
EP4173619A3 (en) 2023-07-19
KR20150115846A (ko) 2015-10-14
US10420737B2 (en) 2019-09-24
LT3069733T (lt) 2022-11-25
ES2929945T3 (es) 2022-12-05
EP3069733A4 (en) 2017-08-23
US11534416B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
EA201591435A1 (ru) Новая композиция соединения ацетаминофена без побочного эффекта на печень
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
EA201692443A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
UA108363C2 (uk) Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
EA201391758A1 (ru) Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
BR112015011179A8 (pt) composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
MX2020002078A (es) Composiciones de amantadina, preparaciones de estas y métodos de uso.
CO2020013552A2 (es) Formulación de anticuerpos
UY37550A (es) Nueva formulación que comprende un derivado de bencimidazol
CL2008002025A1 (es) Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.
AR083393A1 (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor
MX2015006011A (es) Pastilla medicinal a base de ibuprofeno sodico dihidratado.
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
RU2015115159A (ru) Лечебно-профилактическая композиция для ухода за полостью рта гематоонкологических больных
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
EA201391827A1 (ru) Соединения [1,2,4]тиадиазин 1,1-диоксида для снижения мочевой кислоты в сыворотке
CR20130324A (es) Enantiómero activo de dodecil-2-(n,n-dimetilamino)- propionato